CIDRAPJordanian, Saudi camels have MERS-CoV-like antibodiesCIDRAPThe suspicion that Middle Eastern respiratory syndrome coronavirus (MERS-CoV) may be widespread in Middle Eastern camels grew today with reports that dromedary camels in Jordan and Saudi …
|
Idelalisib plus rituximab boosts survival in relapsed chronic lymphocytic leukemia
The Oncology Report NEW ORLEANS – Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymphocytic leukemia unsuitable for chemotherapy, according to results from Study 116. The primary endpoint of median … |
Ibrutinib and rituximab trigger 95 percent response rate among CLL patientsHealthCanal.comNearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the …
|
Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing …
SBWire (press release) The pharma report – “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments … |
|
Monoclonal Antibodies Market in Colorectal Cancer to 2019
SBWire (press release) ResearchMoz.us include new market research report”Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth ” to its huge collection of research … |
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells …PR Newswire India (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with…
Economic Times |
Roche, Prothena to develop new antibodies for Parkinson’s disease treatment
Pharmaceutical Business Review Roche and Prothena have agreed to jointly develop and commercialize new antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal antibody for the treatment of Parkinson’s disease (PD). Currently, PRX002 is in preclinical … Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co …4-traders (press release) Roche, Prothena in $600M Parkinson’s…PharmaLive (press release) (subscription) Genetic Engineering News all 32 news articles » |
Emergent announces positive results from phase 1b study of otlertuzumab in …pharmabiz.comEmergent BioSolutions Inc., a specialty pharmaceutical company, has reported preliminary results from a phase Ib single-arm, open-label study evaluating the safe…
India.Com HealthTwo-drug combo of rituximab and pidilizumab could help treat cancerIndia.Com Healthdrugs One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response, and together, they put half of …
Science Codex |
Two-drug combo could help treat cancer
Daily News & Analysis Neelapu said that Rituximab treatment alone usually achieves a 40 percent overall response rate and about 11 percent complete responses, asserting that the side effect profile of the combination is about the same as rituximab alone. He added … Targeted antibody, immune checkpoint blocker rein in follicular lymphomaScience Codex |